CARDINOR AS

Facts

Source: Firmafakta, with business data from public registers.

organisasjonsnummer:

815714512

navn:

CARDINOR AS

organisasjonsform:

kode:

AS

beskrivelse:

Aksjeselskap

naeringskode1:

kode:

71.129

beskrivelse:

Annen teknisk konsulentvirksomhet

antallAnsatte:

not reported by source

hjemmeside:

www.cardinor.com

epostadresse:

not reported by source

telefon:

not reported by source

forretningsadresse:

adresse:

Lørenveien 73A

poststed:

OSLO

postnummer:

0585

kommune:

OSLO

stiftelsesdato:

2015-06-25

registreringsdatoenhetsregisteret:

2015-07-28

aktivitet:

Medisinsk forskning og utvikling, produksjon og salg av diagnostiske, tester. Utnyttelse av lisensrettigheter og konsulentvirksomhet.

vedtektsfestetFormaal:

Å drive medisinsk forskning og utvikling, produksjon og salg av, diagnostiske tester, utnyttelse av lisensrettigheter,, konsulentvirksomhet, eie og forvalte aksjer og andre verdipapirer,, kjøp, utvikling, utleie og salg av fast eiendom; samt deltakelse i, annen næringsvirksomhet.

View the address in Geonorge

Board and other roles

Source: Firmafakta. Also see the separate Brønnøysund lookup under related lookups.

Daglig leder

• Daglig leder: Kristin Sandereid

Regnskapsfører

• Regnskapsfører: ENORA AS

Styre

• Styremedlem: Jonny Østensen
• Styremedlem: Erik Christensen
• Styrets leder: Håkon Sæterøy

Owners

Source: Firmafakta shareholder dataset.

1. INVEN2 AS – 39.09 % (45000 shares, share class: Ordinære aksjer)
2. BIOVENTIX PLC – 12.29 % (14150 shares, share class: Ordinære aksjer)
3. MP PENSJON PK – 8.72 % (10034 shares, share class: Ordinære aksjer)
4. INTERTRADE SHIPPING AS – 6.51 % (7500 shares, share class: Ordinære aksjer)
5. DAG CHRISTIAN CHRISTIANSEN – 3.54 % (4075 shares, share class: Ordinære aksjer)
6. ALEAP AS – 3.26 % (3750 shares, share class: Ordinære aksjer)
7. GEIR ARVE CHRISTENSEN – 3.04 % (3500 shares, share class: Ordinære aksjer)
8. HELGE RØRVIK RØSJØ – 3.04 % (3500 shares, share class: Ordinære aksjer)
9. MATS STRIDSBERG – 3.04 % (3500 shares, share class: Ordinære aksjer)
10. TORBJØRN OMLAND – 3.04 % (3500 shares, share class: Ordinære aksjer)
11. FRANK FRANTZEN – 1.79 % (2063 shares, share class: Ordinære aksjer)
12. IIG PLC – 1.58 % (1823 shares, share class: Ordinære aksjer)
13. 2M-INVEST AS – 1.54 % (1775 shares, share class: Ordinære aksjer)
14. THOMAS LEIF LYCHE – 1.43 % (1650 shares, share class: Ordinære aksjer)
15. FRENICO AS – 1.3 % (1500 shares, share class: Ordinære aksjer)
16. TRULS INVEST AS – 1.24 % (1430 shares, share class: Ordinære aksjer)
17. RONNY HERMANSEN – 0.87 % (1000 shares, share class: Ordinære aksjer)
18. ARNE LUDVIG FAAREN – 0.76 % (875 shares, share class: Ordinære aksjer)
19. ALRUTECH AS – 0.74 % (848 shares, share class: Ordinære aksjer)
20. NICOLAI ANDREAS EGER – 0.72 % (825 shares, share class: Ordinære aksjer)
21. INVITRODIA AS – 0.55 % (635 shares, share class: Ordinære aksjer)
22. DAVID EVANS – 0.43 % (490 shares, share class: Ordinære aksjer)
23. LS PARTNERS AS – 0.33 % (375 shares, share class: Ordinære aksjer)
24. MIKLA INVEST AS – 0.26 % (300 shares, share class: Ordinære aksjer)
25. SVEIN WILHELM FAYE LIEN – 0.22 % (250 shares, share class: Ordinære aksjer)
26. TORE GRØTTUM – 0.22 % (250 shares, share class: Ordinære aksjer)
27. STORKLEIVEN AS – 0.17 % (200 shares, share class: Ordinære aksjer)
28. BJØRN FUGLAAS – 0.15 % (167 shares, share class: Ordinære aksjer)
29. GETICA AB – 0.15 % (167 shares, share class: Ordinære aksjer)

Fetch a longer owner list

Company holdings

No holdings found.

Grants and support

Sources provided through Firmafakta: Innovation Norway, the EU, the Research Council of Norway and SkatteFUNN.

Innovasjon Norge (3)

3 results

1. fylkesnavn:

   Oslo

   kommunenavn:

   Oslo

   org_nr:

   815714512

   bedriftsnavn:

   CARDINOR AS

   virkemiddelkategori:

   Oppstartstilskudd

   underkategori:

   Landsdekkende etablerertilskudd

   innvilget_belop:

   600000

   innvilget_dato:

   20.12.16

   beslutningsenhet:

   IN Oslo og Akershus

   naringshovedgruppe:

   N - Faglig, vitenskapelig og teknisk tjenesteyting

   naring:

   71.129 Annen teknisk konsulentvirksomhet

   type_finansiering:

   Tilskudd

2. fylkesnavn:

   Oslo

   kommunenavn:

   Oslo

   org_nr:

   815714512

   bedriftsnavn:

   CARDINOR AS

   virkemiddelkategori:

   Innovasjonstilskudd

   underkategori:

   Forsknings- og utviklingstilskudd

   innvilget_belop:

   1780900

   innvilget_dato:

   20.06.24

   beslutningsenhet:

   IN Viken

   naringshovedgruppe:

   N - Faglig, vitenskapelig og teknisk tjenesteyting

   naring:

   71.129 Annen teknisk konsulentvirksomhet

   type_finansiering:

   Tilskudd

3. fylkesnavn:

   Oslo

   kommunenavn:

   Oslo

   org_nr:

   815714512

   bedriftsnavn:

   CARDINOR AS

   virkemiddelkategori:

   Oppstartstilskudd

   underkategori:

   Landsdekkende etablerertilskudd

   innvilget_belop:

   100000

   innvilget_dato:

   01.09.15

   beslutningsenhet:

   IN Oslo og Akershus

   naringshovedgruppe:

   N - Faglig, vitenskapelig og teknisk tjenesteyting

   naring:

   71.129 Annen teknisk konsulentvirksomhet

   type_finansiering:

   Tilskudd

EU-tildelinger (2)

2 results

1. id:

   2883

   rammeprogram:

   H2020

   prosjektnr:

   861862

   prosjektkortnavn:

   STRICT

   prosjektnavn:

   SN: The first blood biomarker to accurately STratify mortality Risk In patients with Cardiac arrhyTmia

   organisasjonsnummer:

   815714512

   organisasjonsnavn:

   CARDINOR AS

   kontrakt_startdato:

   15.12.2019 00:00

   kontrakt_sluttdato:

   14.12.2020 00:00

   innvilget_belop:

   119805

   program:

   INNOSUPSME

   programomrade:

   Industrial Leadership

2. id:

   1437

   rammeprogram:

   H2020

   prosjektnr:

   876600

   prosjektkortnavn:

   SN-marker

   prosjektnavn:

   Secretoneurin (SN): the first blood biomarker to accurately stratify mortality risk in patients with cardiac arrhythmia

   organisasjonsnummer:

   815714512

   organisasjonsnavn:

   CARDINOR AS

   kontrakt_startdato:

   01.10.2019 00:00

   kontrakt_sluttdato:

   29.02.2020 00:00

   innvilget_belop:

   50000

   program:

   INNOSUPSME

   programomrade:

   Industrial Leadership

Forskningsrådet (7)

7 results

1. id:

   68853

   prosjektnummer:

   327882

   prosjekttittel:

   widenSN - New gold standard biomarker for Heart Failure (HF) patients

   prosjektstart:

   2021

   prosjektslutt:

   2024

   prosjektansvarlig_navn:

   CARDINOR AS

   organisasjonsnummer:

   815714512

   sokt_belop:

   Kardiologi

   tildelt_belop:

   0.0

   virkemiddel:

   Programmer

   aktivitet:

   Brukerstyrte innovasjonsprogrammer

2. id:

   69262

   prosjektnummer:

   328988

   prosjekttittel:

   Secretoneurin: the first blood biomarker that strongly predicts mortality, re-hospitalization and need for ICDs in HEart Failure patients

   prosjektstart:

   2021

   prosjektslutt:

   2021

   prosjektansvarlig_navn:

   CARDINOR AS

   organisasjonsnummer:

   815714512

   sokt_belop:

   Helsefag

   tildelt_belop:

   0.0

   virkemiddel:

   Nettverkstiltak

   aktivitet:

   Internasjonale nettverkstiltak

3. id:

   54616

   prosjektnummer:

   300043

   prosjekttittel:

   Clinical validation of secretoneurin as a risk marker for arrythmia

   prosjektstart:

   2019

   prosjektslutt:

   2019

   prosjektansvarlig_navn:

   CARDINOR AS

   organisasjonsnummer:

   815714512

   sokt_belop:

   Medisinsk teknologi

   tildelt_belop:

   0.0

   virkemiddel:

   Nettverkstiltak

   aktivitet:

   Internasjonale nettverkstiltak

4. id:

   49301

   prosjektnummer:

   285371

   prosjekttittel:

   E!11989 Secretoneurin (SN): a breakthrough blood biomarker for heart disease and sudden Cardiac Arrest risk

   prosjektstart:

   2018

   prosjektslutt:

   2021

   prosjektansvarlig_navn:

   CARDINOR AS

   organisasjonsnummer:

   815714512

   sokt_belop:

   Medisinsk teknologi

   tildelt_belop:

   0.0

   virkemiddel:

   Frittstående prosjekter

   aktivitet:

   Internasjonal prosjektstøtte

5. id:

   54048

   prosjektnummer:

   298351

   prosjekttittel:

   SN: the first blood biomarker to accurately stratify mortality risk in patients with cardiac arrhythmia

   prosjektstart:

   2018

   prosjektslutt:

   2020

   prosjektansvarlig_navn:

   CARDINOR AS

   organisasjonsnummer:

   815714512

   sokt_belop:

   Medisinsk teknologi

   tildelt_belop:

   0.0

   virkemiddel:

   Nettverkstiltak

   aktivitet:

   Internasjonale nettverkstiltak

6. id:

   42783

   prosjektnummer:

   270425

   prosjekttittel:

   Biomarkers for arrhythmia

   prosjektstart:

   2016

   prosjektslutt:

   2017

   prosjektansvarlig_navn:

   CARDINOR AS

   organisasjonsnummer:

   815714512

   sokt_belop:

   Tverr/flerfaglig teknologi og andre fagområder

   tildelt_belop:

   0.0

   virkemiddel:

   Nettverkstiltak

   aktivitet:

   Internasjonale nettverkstiltak

7. id:

   37284

   prosjektnummer:

   257358

   prosjekttittel:

   Cardiac Arrhythmia Biomarker

   prosjektstart:

   2015

   prosjektslutt:

   2016

   prosjektansvarlig_navn:

   CARDINOR AS

   organisasjonsnummer:

   815714512

   sokt_belop:

   Tverr/flerfaglig teknologi og andre fagområder

   tildelt_belop:

   0.0

   virkemiddel:

   Nettverkstiltak

   aktivitet:

   Internasjonale nettverkstiltak

SkatteFUNN (6)

6 results

1. id:

   72125

   innsendt_dato:

   2024-09-01

   prosjektnummer:

   1121

   bedriftsnavn:

   CARDINOR AS

   prosjekttittel:

   Klinisk validering av secretoneurin biomarkør test

   organisasjonsnummer:

   815714512

   fylke:

   Oslo

   kommunenavn:

   Oslo

   poststed:

   not reported by source

   soknad_godkjent:

   not reported by source

   soknad_avslatt:

   not reported by source

   vedtaksdato:

   na

   prosjekt_fra_ar:

   2024

   prosjekt_til_ar:

   2025

   sammendrag:

   CardiNor AS is a Norwegian biotech company established in June 2015 to develop and commercialise assays for secretoneurin (SN), an important new biomarker for cardiovascular and kidney disease (CVD). Patents have been granted in the US and Europe. In addition to our CE marked SN ELISA we have developed with the support of NFR, IPN project number 327882 widen SN, a bead-based assay for high throughput platforms that can easily be adopted on the immunoassay platform of the major IVD companies like Roche, Abbot, Siemens etc. We know that SN predicts death (100% certain) and we now see support for SN finding patients who may be relevant for treatment for problems with cardio-renal axis= SGLT2-I, GLP1-RA or specific aldosterone inhibitors (Finerenone). The aim of this project is to expand the clinical use of our products by conducting numerous clinician trials of patients with cardiovascular and kidney disease.

2. id:

   62819

   innsendt_dato:

   2021-08-30

   prosjektnummer:

   330202

   bedriftsnavn:

   CARDINOR AS

   prosjekttittel:

   widenSN

   organisasjonsnummer:

   815714512

   fylke:

   Oslo

   kommunenavn:

   Oslo

   poststed:

   OSLO

   soknad_godkjent:

   JA

   soknad_avslatt:

   NEI

   vedtaksdato:

   2021-09-17

   prosjekt_fra_ar:

   2021

   prosjekt_til_ar:

   2023

   sammendrag:

   Heart failure (HF) affects about 64.3 million patients worldwide and is one of the costliest medical conditions due to long hospitalisations and frequent readmissions., HF patients have a high risk of sudden cardiac death (SCD) and 35% of them die in the first year. While there is no shortage of treatment options aimed at lowering the mortality risk of HF patients, the challenge is to accurately assess (and monitor) the patient’s risk for morbidity and mortality. A biomarker test to help identifying those HF patients could allow, for the first time, a personalization of the dose of drugs for each HF patient based on its risk profile, allowing a more informed balance between the drug’s side effects and patient’s risks. CardiNor has exclusive rights to the cardiac biomarker Secretoneurin (SN), an independent and strong predictor of mortality for HF, and other cardiovascular-related conditions like acute respiratory failure and severe sepsis. An SN test provide prognostic information that no other cardiac biomarker test offers, so there are valuable opportunities underlying the widespread use of SN in clinical practice worldwide. We will benefit from the IPN project to i) Generate substantial clinical evidence to support clinical guidance of how drugs prescribed for HF should be uptitrated per SN risk level to minimize risks, so all HF patients receive the best possible therapy over time; and ii) Obtain a stable, reproducible, and easily manufacturable assay that can be used as the core building block for a novel SN test in high-throughput Core Lab analysers of major IVD suppliers. widenSN is the opportunity for partners to jointly approach the global cardiac biomarkers market. SN holds potential to become a multi-million euro/year opportunity from 2024 onwards.

3. id:

   62820

   innsendt_dato:

   2021-08-30

   prosjektnummer:

   330203

   bedriftsnavn:

   CARDINOR AS

   prosjekttittel:

   SN-CE marking

   organisasjonsnummer:

   815714512

   fylke:

   Oslo

   kommunenavn:

   Oslo

   poststed:

   OSLO

   soknad_godkjent:

   JA

   soknad_avslatt:

   NEI

   vedtaksdato:

   2021-09-17

   prosjekt_fra_ar:

   2021

   prosjekt_til_ar:

   2022

   sammendrag:

   CardiNor AS is a Norwegian biotech company established in June 2015 to develop and commercialise assays for secretoneurin (SN), an important new biomarker for cardiovascular disease (CVD). SN is the only biomarker shown to be associated with biological processes linked to heart Ca2+ handling. This unique biological function explains why SN presents as an independent and strong predictor of mortality in major patient cohorts, including ventricular arrhythmia, acute heart failure, acute respiratory failure patients with CVD and severe sepsis. We have developed an easy to use ELISA (enzyme-linked immunosorbent assay) blood test to address the vast and untapped market potential in CVD patient diagnosis, risk stratification and monitoring. We are conducting further clinical documentation and testing to gain regulatory approval in Europe, CE marking. The CardiNor easy-to-use blood test SN ELISA will help to identify patients with heart disease who will benefit from ICD treatment. The current technology available for measuring SN is an RIA (radioimmunoassay) not suitable for routine or clinical use. Our new test based on ELISA technology that is very well established in both clinical research and routine and can easily be adopted on platforms such as Cobas by Roche and Architect by Abbott.

4. id:

   37967

   innsendt_dato:

   2015-09-01

   prosjektnummer:

   254287

   bedriftsnavn:

   CARDINOR AS

   prosjekttittel:

   Utvikling og dokumentasjon Secretoneurin som biomarkør for hjertekar sykdom

   organisasjonsnummer:

   815714512

   fylke:

   Oslo

   kommunenavn:

   Oslo

   poststed:

   OSLO

   soknad_godkjent:

   JA

   soknad_avslatt:

   NEI

   vedtaksdato:

   2015-09-11

   prosjekt_fra_ar:

   2015

   prosjekt_til_ar:

   2017

   sammendrag:

   not reported by source

5. id:

   69230

   innsendt_dato:

   2023-09-01

   prosjektnummer:

   348973

   bedriftsnavn:

   CARDINOR AS

   prosjekttittel:

   SN ELISA CE IVDR marking

   organisasjonsnummer:

   815714512

   fylke:

   Oslo

   kommunenavn:

   Oslo

   poststed:

   OSLO

   soknad_godkjent:

   JA

   soknad_avslatt:

   NEI

   vedtaksdato:

   2023-12-18

   prosjekt_fra_ar:

   2023

   prosjekt_til_ar:

   2025

   sammendrag:

   CardiNor AS is a Norwegian diagnostic company established in June 2015 to develop and commercialise assays for secretoneurin (SN), an important new biomarker for cardiovascular disease (CVD). SN is the only biomarker shown to be associated with biological processes linked to heart Ca2+ handling. This unique biological function explains why SN presents as an independent and strong predictor of mortality in major patient cohorts, including ventricular arrhythmia, acute heart failure, acute respiratory failure patients with CVD and severe sepsis. We have developed an easy to use ELISA (enzyme-linked immunosorbent assay) blood test to address the vast and untapped market potential in CVD patient diagnosis, risk stratification and monitoring. The test was CE marked according to IVDD 98/79/EC in December 2021 and is now commercially available in the US (research only) and in key markets in Europe through our network of distributors. We are conducting further clinical documentation and testing to gain regulatory approval in Europe according to the new IVDR (EU) 2017/746.

6. id:

   52745

   innsendt_dato:

   2018-12-31

   prosjektnummer:

   298372

   bedriftsnavn:

   CARDINOR AS

   prosjekttittel:

   BioMarkSN

   organisasjonsnummer:

   815714512

   fylke:

   Oslo

   kommunenavn:

   Oslo

   poststed:

   OSLO

   soknad_godkjent:

   JA

   soknad_avslatt:

   NEI

   vedtaksdato:

   2019-01-29

   prosjekt_fra_ar:

   2019

   prosjekt_til_ar:

   2020

   sammendrag:

   CardiNor AS is a Norwegian biotech company established in June 2015 to develop and commercialise assays for secretoneurin (SN), an important new biomarker for cardiovascular disease (CVD). SN is the only biomarker shown to be associated with biological processes linked to cardiomyocyte Ca2+ handling (1). This unique biological function explains why SN presents as an independent and strong predictor of mortality in all major patient cohorts, including ventricular arrhythmia, acute heart failure, acute respiratory failure patients with CVD and severe sepsis. We are currently developing an easy to use ELISA (enzyme-linked immunosorbent assay) blood test to address the vast and untapped market potential in CVD patient diagnosis, risk stratification and monitoring. This will also involve clinical documentation, regulatory filing and market awareness programs. Cardiomyocyte Ca2+ imbalance is at the core of most triggered arrhythmias in CVD, but current biomarkers (troponins and BNP) do not reflect Ca2+ regulation. Accordingly, methods to identify and monitor patients with cardiomyocyte Ca2+ imbalance and increased risk of VT/VF are highly warranted. As the only biomarker associated with Ca2+ status, SN is ideally suited for this purpose. Moreover, high SN concentrations are also a strong indication of the need to follow up with ECGs, echocardiography, and other examinations (angiography, cardiac MRI, PET-CT, etc.) to determine whether there are signs of structural or functional heart disease. CardiNor is now developing an easy-to-use blood test for SN to help identify patients with heart disease who will benefit from ICD treatment. The current technology available for measuring SN is an RIA (radioimmunoassay) not suitable for routine or clinical use. We are developing a new test based on ELISA technology that is very well established in both clinical research and routine and can easily be adopted on platforms such as Cobas by Roche and Architect by Abbott.

Subunits

• CARDINOR AS AVD BODØ (927804751)
• CARDINOR AS AVD OSLO (915735088)

Open positions

count:

0

stillinger:

No results.

Related lookups

• Doffin notices where CARDINOR AS is the buyer
• Search broadly for CARDINOR AS in Doffin
• Open positions related to CARDINOR AS
• Latest financial statement
• Patents and trademarks
• Official entity information from the Brønnøysund Register Centre
• Official roles from the Brønnøysund Register Centre
• Corporate group structure from the Brønnøysund Register Centre